– $ 0.17 Earnings Per Share Expected for Sol-Gel Technologies Ltd. (NASDAQ: SLGL) This Quarter


Equities analysts predict that Sol-Gel Technologies Ltd. (NASDAQ: SLGLGet Rating) will report earnings of ($ 0.17) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Sol-Gel Technologies’ earnings, with estimates ranging from ($ 0.19) to ($ 0.15). Sol-Gel Technologies reported earnings per share of ($ 0.35) during the same quarter last year, which would suggest a positive year-over-year growth rate of 51.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Sol-Gel Technologies will report full year earnings of ($ 0.61) per share for the current fiscal year, with EPS estimates ranging from ($ 0.82) to ($ 0.30). For the next fiscal year, analysts forecast that the business will post earnings of ($ 0.14) per share, with EPS estimates ranging from ($ 0.15) to ($ 0.13). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that follow Sol-Gel Technologies.

Sol-Gel Technologies (NASDAQ: SLGLGet Rating) last posted its quarterly earnings data on Wednesday, March 30th. The company reported $ 0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $ 0.06 by $ 0.55. Sol-Gel Technologies had a return on equity of 3.62% and a net margin of 5.52%. The company had revenue of $ 20.81 million for the quarter, compared to analysts’ expectations of $ 18.37 million.

Several research analysts recently issued reports on the stock. HC Wainwright increased their price target on shares of Sol-Gel Technologies from $ 20.00 to $ 21.00 and gave the stock a “buy” rating in a report on Monday, April 25th. Zacks Investment Research cut shares of Sol-Gel Technologies from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 21st. Finally, Raymond James dropped their target price on shares of Sol-Gel Technologies from $ 21.00 to $ 17.00 and set a “strong-buy” rating for the company in a report on Friday, April 1st.

Several hedge funds have recently added to or reduced their stakes in SLGL. Raymond James Financial Services Advisors Inc. grew its position in shares of Sol-Gel Technologies by 11.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 143,205 shares of the company’s stock valued at $ 1,064,000 after purchasing an additional 14,194 shares during the last quarter. We Are One Seven LLC acquired a new stake in Sol-Gel Technologies during the fourth quarter worth approximately $ 74,000. Raymond James & Associates boosted its position in Sol-Gel Technologies by 25.4% during the first quarter. Raymond James & Associates now owns 47,492 shares of the company’s stock worth $ 350,000 after acquiring an additional 9,631 shares during the last quarter. Finally, Susquehanna International Group LLP boosted its position in Sol-Gel Technologies by 34.0% during the fourth quarter. Susquehanna International Group LLP now owns 16,862 shares of the company’s stock worth $ 125,000 after acquiring an additional 4,275 shares during the last quarter.

SLGL stock opened at $ 6.33 on Friday. Sol-Gel Technologies has a 12-month low of $ 5.50 and a 12-month high of $ 14.50. The business’s 50-day moving average is $ 6.79 and its 200 day moving average is $ 7.27.

Sol-Gel Technologies Company Profile (Get Rating)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.

Featured Stories

Get a free copy of the Zacks research report on Sol-Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for Sol-Gel Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sol-Gel Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment